<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d291">
    <sentence id="DDI-DrugBank.d291.s0" text="When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.">
        <entity id="DDI-DrugBank.d291.s0.e0" charOffset="5-11"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s0.e1" charOffset="16-29"
            type="brand" text="Bezalip retard"/>
        <entity id="DDI-DrugBank.d291.s0.e2" charOffset="146-152"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s0.e3" charOffset="158-171"
            type="brand" text="Bezalip retard"/>
        <entity id="DDI-DrugBank.d291.s0.e4" charOffset="199-233"
            type="group" text="anticoagulants of the coumarin type"/>
        <ddi id="DDI-DrugBank.d291.s0.d0" e1="DDI-DrugBank.d291.s0.e2"
            e2="DDI-DrugBank.d291.s0.e4" type="effect"/>
        <ddi id="DDI-DrugBank.d291.s0.d1" e1="DDI-DrugBank.d291.s0.e3"
            e2="DDI-DrugBank.d291.s0.e4" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s1" text="For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters">
        <entity id="DDI-DrugBank.d291.s1.e0" charOffset="33-45"
            type="drug" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d291.s1.e1" charOffset="108-114"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s1.e2" charOffset="119-125"
            type="brand" text="Bezalip"/>
        <ddi id="DDI-DrugBank.d291.s1.d0" e1="DDI-DrugBank.d291.s1.e0"
            e2="DDI-DrugBank.d291.s1.e1" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s1.d1" e1="DDI-DrugBank.d291.s1.e0"
            e2="DDI-DrugBank.d291.s1.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s2" text="."/>
    <sentence id="DDI-DrugBank.d291.s3" text="- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.">
        <entity id="DDI-DrugBank.d291.s3.e0" charOffset="16-29"
            type="group" text="sulphonylureas"/>
        <entity id="DDI-DrugBank.d291.s3.e1" charOffset="35-41"
            type="drug" text="insulin"/>
        <entity id="DDI-DrugBank.d291.s3.e2" charOffset="62-68"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s3.e3" charOffset="73-86"
            type="brand" text="Bezalip retard"/>
        <ddi id="DDI-DrugBank.d291.s3.d0" e1="DDI-DrugBank.d291.s3.e0"
            e2="DDI-DrugBank.d291.s3.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d291.s3.d1" e1="DDI-DrugBank.d291.s3.e0"
            e2="DDI-DrugBank.d291.s3.e3" type="effect"/>
        <ddi id="DDI-DrugBank.d291.s3.d2" e1="DDI-DrugBank.d291.s3.e1"
            e2="DDI-DrugBank.d291.s3.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d291.s3.d3" e1="DDI-DrugBank.d291.s3.e1"
            e2="DDI-DrugBank.d291.s3.e3" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s4" text="This may be due to an improved glucose utilization with simultaneous reduction in insulin requirement">
        <entity id="DDI-DrugBank.d291.s4.e0" charOffset="82-88"
            type="drug" text="insulin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s5" text="."/>
    <sentence id="DDI-DrugBank.d291.s6" text="- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.">
        <entity id="DDI-DrugBank.d291.s6.e0" charOffset="211-228"
            type="group" text="immuno-suppressant"/>
        <entity id="DDI-DrugBank.d291.s6.e1" charOffset="254-264"
            type="drug" text="bezafibrate"/>
        <ddi id="DDI-DrugBank.d291.s6.d0" e1="DDI-DrugBank.d291.s6.e0"
            e2="DDI-DrugBank.d291.s6.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s7" text="Accordingly, renal function should be closely monitored in these patients and, in the event of relevant significant changes in laboratory parameters, bezafibrate should, if necessary, be discontinued">
        <entity id="DDI-DrugBank.d291.s7.e0" charOffset="150-160"
            type="drug" text="bezafibrate"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s8" text="."/>
    <sentence id="DDI-DrugBank.d291.s9" text="- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired">
        <entity id="DDI-DrugBank.d291.s9.e0" charOffset="7-13"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s9.e1" charOffset="18-31"
            type="brand" text="Bezalip retard"/>
        <entity id="DDI-DrugBank.d291.s9.e2" charOffset="59-79"
            type="group" text="anion-exchange resins"/>
        <entity id="DDI-DrugBank.d291.s9.e3" charOffset="87-101"
            type="drug" text="cholestryramine"/>
        <entity id="DDI-DrugBank.d291.s9.e4" charOffset="209-215"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s9.e5" charOffset="220-233"
            type="brand" text="Bezalip retard"/>
        <ddi id="DDI-DrugBank.d291.s9.d0" e1="DDI-DrugBank.d291.s9.e0"
            e2="DDI-DrugBank.d291.s9.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s9.d1" e1="DDI-DrugBank.d291.s9.e0"
            e2="DDI-DrugBank.d291.s9.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s9.d2" e1="DDI-DrugBank.d291.s9.e1"
            e2="DDI-DrugBank.d291.s9.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s9.d3" e1="DDI-DrugBank.d291.s9.e1"
            e2="DDI-DrugBank.d291.s9.e3" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d291.s10" text="."/>
    <sentence id="DDI-DrugBank.d291.s11" text="- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.">
        <entity id="DDI-DrugBank.d291.s11.e0" charOffset="2-29"
            type="drug" text="Perhexiline hydrogen maleate"/>
        <entity id="DDI-DrugBank.d291.s11.e1" charOffset="34-47"
            type="group" text="MAO-inhibitors"/>
        <entity id="DDI-DrugBank.d291.s11.e2" charOffset="117-123"
            type="brand" text="Bezalip"/>
        <entity id="DDI-DrugBank.d291.s11.e3" charOffset="128-141"
            type="brand" text="Bezalip retard"/>
        <ddi id="DDI-DrugBank.d291.s11.d0" e1="DDI-DrugBank.d291.s11.e0"
            e2="DDI-DrugBank.d291.s11.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s11.d1" e1="DDI-DrugBank.d291.s11.e0"
            e2="DDI-DrugBank.d291.s11.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s11.d2" e1="DDI-DrugBank.d291.s11.e1"
            e2="DDI-DrugBank.d291.s11.e2" type="advise"/>
        <ddi id="DDI-DrugBank.d291.s11.d3" e1="DDI-DrugBank.d291.s11.e1"
            e2="DDI-DrugBank.d291.s11.e3" type="advise"/>
    </sentence>
</document>
